title: Fuzheng Yiliu Granule inhibits the growth of hepatocellular cancer by regulating immune function and inducing apoptosis in vivo and in vitro.
abstract: OBJECTIVE
  To study the inhibitory effect of Fuzheng Yiliu Granule (FYG) on hepatocellular cancer (HCC) and investigate the mechanism mediating its bioactivity.
  
  
  METHODS
  H22 tumor-bearing ICR mice were treated with FYG [3.6 g/(kg·d)] for 5 days. Tumor volume and tumor weight, percentages of CD3(+), CD4(+), CD8(+), and natural killer (NK) cells in peripheral blood, tumor apoptosis and serum levels of interleukin-2 (IL-2), and tumor necrosis factor-α (TNF-α) were evaluated. FYG-containing serum was prepared from SD rats treated for 7 days [high dose 3.6 g/(kg·d); middle dose 1.8 g/(kg·d); low dose 0.9 g/(kg·d)]. Cell cycle, cell viability, and apoptosis were evaluated after HepG2 cell line was cultured in FYG-containing serum for 48 h. The levels of IL-2 and TNF-α in FYG-containing serum were also determined.
  
  
  RESULTS
  FYG produced a potent antitumor effect (P<0.01) and induced marked apoptosis of the tumor tissue (P<0.05). Mice treated with FYG had higher percentages of CD3(+) and CD4(+) (P<0.05), and more NK cells (P<0.01) in the peripheral blood than those in the animals treated with normal saline. Mice receiving FYG had the highest serum levels of IL-2 and TNF-α (P<0.01). High-dose FYG-containing serum significantly decreased HepG2 cell viability, inhibited cell proliferation (P<0.05), and induced apoptosis (P<0.01). In addition, the levels of IL-2 and TNF-α of high-dose-containing serum were higher than the blank serum (P<0.01).
  
  
  CONCLUSIONS
  FYG could inhibit HCC growth by regulating immune function and inducing apoptosis of tumor cells in vivo and in vitro.
authors: Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, China.
authors: Zhi-yun
authors: ZY
authors: Cao
authors: Xu-zheng
authors: XZ
authors: Chen
authors: Lian-ming
authors: LM
authors: Liao
authors: Jun
authors: J
authors: Peng
authors: Hai-xia
authors: HX
authors: Hu
authors: Zhi-zhen
authors: ZZ
authors: Liu
authors: Jian
authors: J
authors: Du
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects*; D006528:Carcinoma, Hepatocellular / Q000097:blood / Q000276:immunology* / Q000473:pathology*; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D004365:Drugs, Chinese Herbal / Q000494:pharmacology*; D056945:Hep G2 Cells; D006801:Humans; D007376:Interleukin-2 / Q000096:biosynthesis; D008113:Liver Neoplasms / Q000097:blood / Q000276:immunology* / Q000473:pathology*; D018655:Lymphocyte Count; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D051381:Rats; D044967:Serum; D047368:Tumor Burden / Q000187:drug effects; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis; D023041:Xenograft Model Antitumor Assays
chemical_list: D004365:Drugs, Chinese Herbal; D007376:Interleukin-2; D014409:Tumor Necrosis Factor-alpha; C533482:fuzheng yiliu